Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 3/20 | 0.45 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.41 |
| ▸ | RHEB | Q15382 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.34 |
| ▸ | FBP1 | P09467 | 1/20 | 0.34 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29507097 | 1.00 | AHR (0.45) | AHRHTR6CYP2A6NR4A2RHEB | |
| Formic Acid SCHEMBL28972975 | 0.89 | CYP2A6 (0.42) | AHRHTR6CYP2A6NR4A2RHEB | |
| SCHEMBL1294597 | 0.78 | RXFP1 (0.47) | AHRCYP2A6ALDH1A1HPGDALOX15 | |
| SCHEMBL29713811 | 0.78 | RXFP1 (0.47) | AHRCYP2A6ALDH1A1HPGDALOX15 | |
| SCHEMBL29644241 | 0.78 | AHR (0.54) | AHRHTR6CYP2A6NR4A2RHEB | |
| SCHEMBL1020056 | 0.78 | AHR (0.54) | AHRHTR6CYP2A6NR4A2RHEB | |
| SCHEMBL17127673 | 0.76 | METAP2 (0.37) | ALDH1A1HPGDALOX15HSD17B10RXFP1 | |
| SCHEMBL25383240 | 0.75 | AHR (0.45) | AHRHTR6CYP2A6NR4A2RHEB | |
| SCHEMBL1021334 | 0.75 | AHR (0.45) | AHRHTR6CYP2A6NR4A2RHEB | |
| SCHEMBL29507054 | 0.75 | AHR (0.45) | AHRHTR6CYP2A6NR4A2RHEB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3870583-B1 | SUBSTITUTED INDOLE AND INDAZOLE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20250325677-A1 | STAT6 DEGRADERS | GILEAD SCIENCES INC (US) | 2025-10-23 | — | — | US | disclosed |
| US-12180215-B2 | Substituted pyrrolo[3,4-d]imidazoles as JAK inhibitors | HENAN MEDINNO PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2024-12-31 | — | — | US | disclosed |
| US-12172995-B2 | Substituted indole and indazole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-12-24 | — | — | US | disclosed |
| EP-3932919-B1 | JAK INHIBITOR COMPOUND AND USE THEREOF | HENAN MEDINNO PHARMACEUTICAL TECH CO LTD (CN) | 2024-06-26 | — | — | EP | disclosed |
| US-20230374007-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2023-11-23 | — | — | US | disclosed |
| US-20230374007-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2023-11-23 | — | — | US | disclosed |
| US-20230339886-A1 | REV-ERB AGONISTS FOR THE TREATMENT OF TH17-MEDIATED INFLAMMATORY DISORDERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230339886-A1 | REV-ERB AGONISTS FOR THE TREATMENT OF TH17-MEDIATED INFLAMMATORY DISORDERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230201165-A1 | JAK INHIBITOR COMPOUND FOR TREATING SEVERE PNEUMONIA | HENAN MEDINNO PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2023-06-29 | — | — | US | disclosed |
| CN-102046240-B | Novel P2X7R antagonists and their use | AFFECTIS PHARMACEUTICALS AG | 2014-06-25 | — | — | CN | disclosed |
| US-8569334-B2 | P2X7R antagonists and their use | AFFECTIS PHARMACEUTICALS AG (DE) | 2013-10-29 | — | — | US | disclosed |
| US-20130197046-A1 | NOVEL P2X7R ANTAGONISTS AND THEIR USE | AFFECTIS PHARMACEUTICALS AG (DE) | 2013-08-01 | — | — | US | disclosed |
| US-20120302597-A1 | NOVEL P2X7R ANTAGONISTS AND THEIR USE | AFFECTIS PHARMACEUTICALS AG (DE) | 2012-11-29 | — | — | US | disclosed |
| US-8232290-B2 | P2X7R antagonists and their use | AFFECTIS PHARMACEUTICALS AG (DE) | 2012-07-31 | — | — | US | disclosed |
| CN-102046240-A | Novel P2X7R antagonists and their use | AFFECTIS PHARMACEUTICALS AG | 2011-05-04 | — | — | CN | disclosed |
| EP-2105164-B1 | Novel P2X7R antagonists and their use | AFFECTIS PHARMACEUTICALS AG (DE) | 2011-01-12 | — | — | EP | disclosed |
| US-20090312366-A1 | NOVEL P2X7R ANTAGONISTS AND THEIR USE | AFFECTIS PHARMACEUTICALS AG (DE) | 2009-12-17 | — | — | US | disclosed |
| WO-2009118175-A1 | NOVEL P2X7R ANTAGONISTS AND THEIR USE | AFFECTIS PHARMACEUTICALS AG (DE) | 2009-10-01 | — | — | WO | disclosed |
| EP-2105164-A1 | Novel P2X7R antagonists and their use | Affectis Pharmaceuticals AG (DE) | 2009-09-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339886-A1 | REV-ERB AGONISTS FOR THE TREATMENT OF TH17-MEDIATED INFLAMMATORY DISORDERS | NR1H2, NR1H3, NR1D1 | AHR 626/4885HTR6 4613/4885CYP2A6 1550/4885 |
| US-20250325677-A1 | STAT6 DEGRADERS | STAT6, STAT5B, STAT1 | AHR 32/4885HTR6 1343/4885CYP2A6 584/4885 |
| US-12180215-B2 | Substituted pyrrolo[3,4-d]imidazoles as JAK inhibitors | JAK1, JAK2, JAK3 | AHR 1342/4885HTR6 3475/4885CYP2A6 1118/4885 |
| US-20230201165-A1 | JAK INHIBITOR COMPOUND FOR TREATING SEVERE PNEUMONIA | JAK1, JAK2, JAK3 | AHR 1987/4885HTR6 4020/4885CYP2A6 1699/4885 |
| US-20230374007-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | RARA, RARG, RARB | AHR 465/4885HTR6 4280/4885CYP2A6 256/4885 |
| US-20130197046-A1 | NOVEL P2X7R ANTAGONISTS AND THEIR USE | P2RX3, P2RX7, P2RX2 | AHR 328/4885HTR6 117/4885CYP2A6 2419/4885 |
| US-20120302597-A1 | NOVEL P2X7R ANTAGONISTS AND THEIR USE | P2RX3, P2RX7, P2RX2 | AHR 328/4885HTR6 117/4885CYP2A6 2419/4885 |
| US-12172995-B2 | Substituted indole and indazole compounds | TLR1, TLR7, IDO1 | AHR 95/4885HTR6 651/4885CYP2A6 2201/4885 |
| US-20090312366-A1 | NOVEL P2X7R ANTAGONISTS AND THEIR USE | P2RX3, P2RX7, P2RX2 | AHR 328/4885HTR6 117/4885CYP2A6 2419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.